

A genetic contribution to risk for postoperative junctional ectopic tachycardia in children undergoing surgery for congenital heart disease

Kristie Y. Borgman, MD, MSCI,* Andrew H. Smith, MD, MSCI,*[†] Jill P. Owen, RN, BSN,* Frank A. Fish, MD,* Prince J. Kannankeril, MD, MSCI*

From the *Thomas P. Graham Jr. Division of Cardiology and [†]Division of Critical Care Medicine, Department of Pediatrics, Monroe Carell Jr. Children's Hospital at Vanderbilt, Vanderbilt University School of Medicine, Nashville, Tennessee.

BACKGROUND Junctional ectopic tachycardia (JET) is a common arrhythmia complicating pediatric cardiac surgery, with many identifiable clinical risk factors but no genetic risk factors to date.

OBJECTIVE To test the hypothesis that the angiotensin-converting enzyme insertion/deletion (ACE I/D) polymorphism associates with postoperative JET.

METHODS DNA samples were collected from children undergoing the Norwood procedure; arterial switch operation; and repairs of Tetralogy of Fallot, balanced atrioventricular septal defect, and ventricular septal defect at a single center. The incidence of postoperative JET was associated with previously identified clinical risk factors and ACE I/D genotype.

RESULTS Of the 174 children who underwent the above-mentioned surgeries, 21% developed JET. Postoperative JET developed in 31% of children with the D/D genotype but only in 16% of those with the I/I genotype or the I/D genotype ($P = .02$). Clinical predictors of JET were selected a priori and included age, inotrope score, cardiopulmonary bypass time, and cross-clamp time. Multivariable logistic regression identified a significant correlation between the D/D genotype and postoperative JET independent of

these predictors (odds ratio = 2.4; 95% confidence interval, 1.04–5.34; $P = .04$). A gene-dose effect was apparent in the homogeneous subset of subjects with atrioventricular septal defect (58% JET in D/D subjects, 12% JET in I/D subjects, and 0% JET in I/I subjects; $P < .01$).

CONCLUSION The common ACE deletion polymorphism is associated with a greater than 2-fold increase in the odds of developing JET in children undergoing surgical repair of atrioventricular septal defect, Tetralogy of Fallot, ventricular septal defect or the Norwood and arterial switch procedures. These findings may support the potential role of the renin-angiotensin-aldosterone system in the etiology of JET.

KEYWORDS Arrhythmia; Pediatrics; Heart defects; congenital; Genetics; ACE polymorphism

ABBREVIATIONS ACE = angiotensin-converting enzyme; AVSD = atrioventricular septal defect; CI = confidence interval; I/D = insertion/deletion; JET = junctional ectopic tachycardia; OR = odds ratio; TOF = Tetralogy of Fallot; VSD = ventricular septal defect

(Heart Rhythm 2011;8:1900–1904) © 2011 Heart Rhythm Society. All rights reserved.

Introduction

Postoperative arrhythmias are a significant concern in the care of children undergoing surgical repair of congenital heart disease. The development of arrhythmias in the postoperative period with accompanying hemodynamic compromise has been repeatedly linked to increased morbidity and mortality.^{1–3} Junctional ectopic tachycardia (JET) is the most commonly observed arrhythmia in children after cardiac surgery,^{3,4} with reported incidences ranging from 6% to 12%.^{5,6} Specific surgical procedures, such as complete repair of Tetralogy of Fallot (TOF) and

atrioventricular septal defect (AVSD), carry particularly high risk, with incidence rates as high as 22%.² While JET is a self-limited arrhythmia that typically resolves within several days, associated increases in heart rate along with loss of atrioventricular synchrony, in the setting of potential systolic or diastolic dysfunction, can be detrimental. Patients who develop JET have increased morbidity, including prolonged ventilation times and intensive care unit stays, and mortality compared with their counterparts without JET.^{2,3,5–8} Pharmacologic therapy may have adverse hemodynamic effects and is sometimes ineffective, and additional treatments ranging from therapeutic hypothermia to catheter ablation to extracorporeal cardiac support may be required, each with variable efficacy and its own related complications.⁹

With such morbidity there has been a search for predictive factors to aid in the anticipation, diagnosis, and treat-

This work was supported by NIH grants HL076265 and 5T32HD060554 as well as National Center for Research Resources/NIH grant 1 UL1 RR024975. **Address for reprints and correspondence:** Dr Kristie Y. Borgman, MD, MSCI, 2200 Children's Way, Suite 5230, Nashville, TN 37232. E-mail address: Kristie.Borgman@Vanderbilt.edu. (Received May 12, 2011; accepted June 27, 2011.)

ment of this postoperative complication. Several studies have reported the clinical risk factors associated with the development of postoperative JET, including younger age, smaller size, longer cardiopulmonary bypass and aortic cross-clamp times, higher complexity of surgery, and the degree of inotropic support,^{5–7,10} yet the genetic contribution to this arrhythmia has not been examined. Given the high frequency of postoperative JET among children requiring certain surgical procedures, we hypothesize that genetic variants that are common in the general population may predispose children to JET, which is manifested only after the insult of certain cardiac surgeries. Evidence is growing that the renin–angiotensin–aldosterone system has proarrhythmic effects,¹¹ and the common insertion/deletion (I/D) polymorphism in the angiotensin-converting enzyme (ACE) gene (rs4646994) has been previously associated with various arrhythmias.^{12,13} The purpose of this study was to test the hypothesis that the ACE I/D polymorphism affects the risk of postoperative JET in children undergoing surgical repair of congenital heart defects.

Methods

Patient population

Pediatric patients undergoing cardiac surgery at the Monroe Carell Jr. Children's Hospital at Vanderbilt and subsequently admitted to the pediatric cardiac intensive care unit from September 2007 to May 2010 were prospectively enrolled. As the risk of JET varies with the type of surgical procedure,² for this study we included only those patients who underwent one of the following operations: the Norwood procedure for hypoplastic left heart syndrome variants, arterial switch operation for transposition of the great arteries, repair of TOF, repair of balanced AVSD, or repair of ventricular septal defect (VSD). Although the specific insult that results in the increased risk of JET for certain surgical procedures is not precisely understood, these procedures were chosen because of the observed high proportion of JET associated with each. Patients undergoing other cardiac surgeries were not included in the analysis as it was felt that even patients with a genetic predisposition to JET would not develop the arrhythmia following surgeries with very low observed incidences of postoperative JET.

Data collection

Perioperative data collection included patient demographics, medical history, preoperative arrhythmias, and operative details including aortic cross-clamp and cardiopulmonary bypass times, medications administered, and laboratory values. Patients underwent continuous monitoring with a full-disclosure telemetry system (Phillips Medical Systems, Bothell, WA) for the duration of their hospitalization. Study personnel reviewed recordings daily, and a pediatric electrophysiologist blinded to the genotype results confirmed all arrhythmias. JET was defined as tachycardia (usually >170 beats/min) with rate > 110% of the preceding sinus rate with the following features: (1) a QRS complex similar to conducted sinus beats; (2) a ventricular rate greater than or

equal to the atrial rate, usually exhibiting a pattern of “warm-up” at initiation, consistent with an automatic mechanism; and (3) ventriculoatrial dissociation, or variable or 1:1 retrograde association.¹⁴ Further diagnostic maneuvers including recording of the atrial electrogram, adenosine, and temporary atrial or ventricular pacing were performed when the diagnosis was unclear with the inspection of telemetry alone. This study was approved by the Vanderbilt University Institutional Review Board for Research on Human Subjects. Written informed consent was obtained from each subject's parent or legal guardian.

Genotyping

Blood or saliva was collected from each patient, and genomic DNA was extracted through the Vanderbilt Center for Human Genetics Research DNA Resources Core by using the Autopure instrument manufactured and supported by Qiagen (Valencia, CA). Genotyping of the common ACE I/D polymorphism was performed by using a TaqMan PCR Core Reagent Kit (Applied Biosystems, Foster City, CA) with slight modifications to the protocol as outlined in Koh et al.¹⁵ Laboratory personnel performing genotyping were unaware of the clinical status of enrolled subjects.

Data analysis

Demographic and clinical data were compared by using the Mann–Whitney *U* test or analysis of variance test for continuous variables and the chi-square test or Fisher's exact test, where appropriate, for categorical variables. Descriptive statistics are shown as medians with ranges for continuous nonnormally distributed data and frequencies with percentages for categorical variables. Hardy–Weinberg equilibrium was assessed by using the chi-square test.¹⁶ Clinical and genetic predictors of JET were selected a priori on the basis of previously published data and include cardiopulmonary bypass time, aortic cross-clamp time, age at surgery, and inotrope score. The inotrope score, which has been previously associated with JET,¹⁰ is a calculated score based on the dose of inotropic medications at the initiation of JET or, in those who do not develop JET, the highest dose the patient receives in the first 3 postoperative days. It was calculated according to the following formula created by Batra et al¹⁰: (dopamine + dobutamine) + (milrinone × 20) + [(epinephrine + norepinephrine) × 100].²

Multivariable logistic regression was then used to assess the effect of genotype on the development of JET independent of the clinical predictors. In addition to the a priori selected variables, those with *P* < .1 in univariate analysis were used in multivariable analysis. The exception to this is body surface area, which was highly correlated with patient age ($r_s = 0.86$). In order to avoid multicollinearity, body surface area was excluded from the multivariate regression.

Because of the number of previously identified variables associated with JET, we conducted a sensitivity analysis by using a propensity score adjustment to assess for a bias through overfitting. A propensity score was calculated by using the beta coefficients of age, aortic cross-clamp time,

cardiopulmonary bypass time, and inotrope score from a binary logistic regression with the D/D genotype as the outcome. In this way, all the a priori selected clinical variables were condensed into one variable. A logistic regression was then performed with the development of JET as the outcome and the propensity score and the D/D genotype as variables. Because of the predominance of Caucasians in the cohort, stratification by race was not possible; hence, a subgroup analysis including only Caucasian subjects was performed. Following analyses of all surgical procedures, the association between the ACE I/D allele and JET was examined in the clinically homogeneous subgroup of patients undergoing repair of AVSD. In addition to having a high incidence of JET, this was the only subgroup without neonatal repairs. In this group, univariate analysis was performed with the a priori selected variables noted above as well as a linear-by-linear association test to assess for a gene-dose effect. Multivariable logistic regression was then performed including all variables with a *P* value of $<.1$ in the univariate analysis. Statistical significance was defined as a 2-tailed *P* value of $<.05$. Statistical analysis was performed by using SPSS statistical package, release 17.0 (SPSS, Inc., Chicago, IL). The authors had full access to and take full responsibility for the integrity of the data. All authors have read and agree to the manuscript as written.

Results

During the 32-month enrollment period, 174 consented patients underwent the above-mentioned surgeries that were selected because of their high risk of JET and were included in the analysis. Thirty-six of these patients (21%) developed postoperative JET. The average heart rate during JET was 185 beats per minute, the average duration was 64 hours, and the onset was most commonly observed within the first 24 hours after surgery. Retrograde conduction was common with dissociation and intermittent sinus capture beats also observed. Therapeutic measures included cooling, atrial pacing, and intravenous amiodarone. Clinical characteristics of the patients are listed in Table 1. Genotype frequencies were similar among the different surgical procedures. The cohort contained 143 Caucasians, 19 African Americans, 10 biracial patients, and 2 Asians. There were no significant differences in allelic frequency or proportion with JET among these subgroups.

The ACE I/D genotype distribution was in Hardy-Weinberg equilibrium (17% I/I, 49% I/D, 34% D/D). There were no significant differences in aortic cross-clamp times or cardiopulmonary bypass times among the ACE genotypes for the entire cohort or for each surgical subgroup. Postoperative JET developed in 31% of children with the D/D genotype but only in 16% of those with the I/I genotype or the I/D genotype (*P* = .02). A significant association was present between JET and bypass time (*P* = .01), aortic cross-clamp time (*P* $<.01$), age at surgery (*P* = .01), and body surface area (*P* $<.01$). In this population, inotrope score did not associate with JET (*P* = .73). The results of the multivariable analysis are given in Table 2. Patients with

Table 1 Demographic and baseline clinical characteristics

	Without JET* (n = 138)	With JET* (n = 36)	<i>P</i>
Age (d)	157 (1–4262)	96.5 (3–229)	.01
Body surface area (m ²)	0.31 (0.17–1.91)	0.26 (0.13–0.47)	$<.01$
Cross-clamp time (min)	51 (21–217)	79 (8–110)	$<.01$
Cardiopulmonary bypass time (min)	111 (53–404)	141 (57–263)	.01
Inotrope score	10 (0–36)	10 (0–25)	.73
Race			.77
Caucasian	114 (80%)	29 (20%)	
Not Caucasian	24 (77%)	7 (23%)	
Gender			.79
Male	80 (80%)	20 (20%)	
Female	58 (78%)	16 (22%)	
ACE I/D Genotype			.02
I/I or I/D	97 (84%)	18 (16%)	
I/I	25 (83%)	5 (17%)	
I/D	72 (86%)	13 (14%)	
D/D	41 (69%)	18 (31%)	
Surgical procedures			.47
Arterial switch	14 (78%)	4 (22%)	
AVSD repair	25 (74%)	9 (27%)	
Norwood	14 (82%)	3 (18%)	
TOF repair	26 (72%)	10 (28%)	
VSD repair	59 (85%)	10 (15%)	

ACE I/D = angiotensin-converting enzyme insertion/deletion; AVSD = atrioventricular septal defect; JET = junctional ectopic tachycardia; TOF = Tetralogy of Fallot; VSD = ventricular septal defect.

*Data are given as medians with ranges for continuous data and as frequencies with percentages for categorical variables.

the D/D genotype had a greater than 2-fold increase in the odds of developing JET as compared with those with the I/I genotype or the I/D genotype after adjusting for aortic cross-clamp and cardiopulmonary bypass times, age, and inotrope score (odds ratio [OR] = 2.4; 95% confidence interval [CI] = 1.04–5.34; *P* = .04). The propensity score and Caucasian subgroup analysis, conducted as sensitivity analyses, yielded similar results (propensity score adjusted OR = 2.2; 95% CI = 1.01–4.60; *P* = .05; Caucasian subgroup adjusted OR = 2.8; 95% CI = 1.08–7.00; *P* = .03), indicating that neither overfitting nor race negates the impact of the D/D genotype on the development of JET.

The association of the D/D genotype with JET was assessed in the homogeneous group of 34 patients undergoing AVSD repair, 9 of whom (27%) developed JET. The Hardy-Weinberg equilibrium was maintained in this subset (15% I/I, 50% I/D, 35% D/D), and the D/D genotype remained a significant predictor of JET (12% JET in I/I or I/D; 56% JET in D/D, *P* $<.01$) in univariate analysis. The only significant predictors of JET in univariate analysis were the ACE polymorphism, aortic cross-clamp time (*P* $<.01$), and bypass time (*P* = .05). Age (*P* = .70) and inotrope score (*P* = .70) were not associated with JET in this clinically homogeneous group. With multivariable analysis, the ACE genotype remained a significant predictor of JET after ad-

Table 2 Multivariable analysis of covariates associated with the development of junctional ectopic tachycardia

Adjusted variable	Adjusted odds ratio (95% confidence interval)	P
D/D genotype	2.4 (1.04–5.34)	.04
Aortic cross-clamp time	1.02 (1.00–1.04)	.04
Cardiopulmonary bypass time	1.00 (0.99–1.01)	.99
Age	0.99 (0.98–0.99)	.01
Inotrope score	0.92 (0.85–0.99)	.03

justing for bypass and aortic cross-clamp times (OR = 25.9; 95% CI = 1.77–378.05; $P = .02$). In addition, a gene–dose effect was seen such that none of the patients with the I/I genotype, 12% of those with the I/D genotype, and 58% of those with the D/D genotype developed JET ($P < .01$). Of note, 68% of this group had Trisomy 21 but there was no significant difference in genotype frequencies or development of JET between those with and without Trisomy 21.

Discussion

This study is the first to demonstrate a genetic predisposition to postoperative JET, the most prevalent arrhythmia in the postoperative period among children undergoing congenital cardiac surgery. Specifically, the ACE D/D genotype displayed a significant association with the development of postoperative JET in this cohort of children undergoing an array of common congenital cardiac operations: arterial switch operation; Norwood procedure; and surgical repair of TOF, VSD, and balanced AVSD. The magnitude of the association is clinically significant, as the D/D genotype more than doubles the odds of developing JET while previously identified clinical predictive factors only slightly increase the odds of this arrhythmia. Furthermore, a gene–dose effect is illustrated in the relatively homogeneous group of patients who had an AVSD repair, supporting a causative association. Determination of a genetic predisposition for postoperative JET could provide an increased ability to predict this arrhythmia and suggest novel treatment modalities that could impact patient management and outcomes. Therefore, further investigation of this association is warranted.

To our knowledge, genetic contributions to the risk for postoperative arrhythmias in children have not been investigated. A genetic predisposition to postoperative JET is suggested by the highly familial nature of nonpostoperative JET.¹⁷ While no specific genes have yet been identified in this rare syndrome, it is presumably caused by variants that are rare in the general population, but with strong effects resulting in the clinical phenotype of JET without requiring the insult of cardiac surgery. Given the relatively common nature of the postoperative form of JET after certain cardiac surgeries, we hypothesized that variants that are common in the general population could result in no arrhythmia phenotype at baseline but would increase the risk for JET when combined with the insult of cardiac surgery. We chose to test the ACE I/D polymorphism because of its frequency

and known proarrhythmic effects, making it a reasonable candidate to increase the risk for postoperative JET.

Whether the association between the D/D ACE genotype and postoperative JET is due to a causative effect is unclear and warrants further investigation. While the precise cellular mechanism of JET is unknown, multiple lines of evidence support a biologically plausible link between the ACE polymorphism and postoperative JET. ACE cleaves angiotensin I into angiotensin II, which triggers multiple signaling pathways, directly modulating membrane ion channels, intracellular calcium handling, and gap junctions, as well as increasing oxidative stress.¹¹ It has been well established that the ACE I/D polymorphism affects plasma ACE levels,¹⁸ cellular levels of angiotensin I and II,¹⁹ and cardiac ACE activity, with higher ACE activity and angiotensin II levels in D/D subjects than in I/I subjects, and intermediate levels in heterozygotes.²⁰ Thus, our finding of higher risk for postoperative JET in D/D subjects, and an apparent gene–dose effect in subjects with AVSD, is consistent with a proarrhythmic state from higher ACE and angiotensin II levels. The polymorphism has been previously associated with atrial fibrillation¹² and reperfusion-induced ventricular arrhythmias,¹⁹ as well as prolonged atrioventricular nodal conduction in patients with structural heart disease.²¹ Our association of the polymorphism with postoperative JET in children may reflect either a direct effect or possibly indirect mechanisms that lead to proarrhythmia.

In addition to identifying patients at higher risk for the development of JET, these results raise the possibility of new preventative treatments for postoperative JET. Postoperative JET is common after procedures with mechanical stretch in the area of the atrioventricular node and in lesions with chronic volume (VSD/AVSD) or pressure (TOF) overload, resulting in myocardial hypertrophy, congestive heart failure, or both. Pulsatile stretch simulating such conditions results in electrical remodeling of ion channels and gap junction proteins in cardiac myocytes,²² and these changes are prevented by pharmacologic angiotensin II blockers.^{23,24} It has previously been shown that response to antiarrhythmic therapy for atrial fibrillation is affected by the ACE genotype.²⁵ Modulating ACE activity with ACE inhibitors or angiotensin receptor blockers specifically in patients with the D/D genotype may decrease the incidence of postoperative JET in this highly susceptible population. In addition, a pharmacogenomic interaction between the ACE I/D polymorphism and beta blockers has been demonstrated in patients with congestive heart failure.²⁶ Transplant-free survival was poorer for patients with the D allele, but only in those not treated with a beta blocker. Given the high adrenergic states associated with postoperative JET, beta blockers may similarly protect susceptible D/D individuals from postoperative JET. Further study of this association and potential pharmacogenomic implications will need to be completed.

Limitations

While this study's findings are clinically relevant and have implications for the management and prevention of postoperative JET, there are limitations. One drawback is the relatively small sample size. Clinical predictors with weaker effects may not be identified, and additional analysis adjusting for patients receiving ACE inhibitors or other medications affecting the renin-angiotensin-aldosterone system could not be performed. Genetic results were not known at the time of surgery; thus, preventive measures could not be tested in those with the D/D genotype. Like all genetic association studies, these results must be replicated.

Conclusion

The incidence of postoperative JET remains high in children after arterial switch operation; Norwood procedure; and repair of TOF, VSD, and AVSD. A common deletion polymorphism in the ACE gene is independently associated with a greater than 2-fold increased risk of postoperative JET in these children, with a stronger effect compared with that of previously established clinical predictors. A gene-dose effect is apparent in the relatively homogeneous subgroup of patients undergoing repair of AVSD. Together, these results support a role for the renin-angiotensin-aldosterone system in the etiology of JET.

References

- Brown KL, Ridout DA, Goldman AP, Hoskote A, Penny DJ. Risk factors for long intensive care unit stay after cardiopulmonary bypass in children. *Crit Care Med* 2003;31:28–33.
- Dodge-Khatami A, Miller OI, Anderson RH, Gil-Jaurena JM, Goldman AP, de Leval MR. Impact of junctional ectopic tachycardia on postoperative morbidity following repair of congenital heart defects. *Eur J Cardiothorac Surg* 2002;21:255–259.
- Rekawek J, Kansy A, Miszczak-Knecht M, et al. Risk factors for cardiac arrhythmias in children with congenital heart disease after surgical intervention in the early postoperative period. *J Thorac Cardiovasc Surg* 2007;133:900–904.
- Delaney JW, Moltedo JM, Dziura JD, Kopf GS, Snyder CS. Early postoperative arrhythmias after pediatric cardiac surgery. *J Thorac Cardiovasc Surg* 2006;131:1296–1300.
- Andreasen JB, Johnsen SP, Ravn HB. Junctional ectopic tachycardia after surgery for congenital heart disease in children. *Intensive Care Med* 2008;34:895–902.
- Hoffman TM, Bush DM, Wernovsky G, et al. Postoperative junctional ectopic tachycardia in children: incidence, risk factors, and treatment. *Ann Thorac Surg* 2002;74:1607–1611.
- Mildh L, Hiippala A, Rautiainen P, Pettila V, Sairanen H, Happonen JM. Junctional ectopic tachycardia after surgery for congenital heart disease: incidence, risk factors and outcome. *Eur J Cardiothorac Surg* 2011;1:75–80.
- Haas NA, Plumpton K, Justo R, Jalali H, Pohlner P. Postoperative junctional ectopic tachycardia (JET). *Z Kardiol* 2004;93:371–380.
- Kelly BP, Gajarski RJ, Ohye RG, Charpie JR. Intravenous induction of therapeutic hypothermia in the management of junctional ectopic tachycardia: a pilot study. *Pediatr Cardiol* 2010;31:11–17.
- Batra AS, Chun DS, Johnson TR, et al. A prospective analysis of the incidence and risk factors associated with junctional ectopic tachycardia following surgery for congenital heart disease. *Pediatr Cardiol* 2006;27:51–55.
- Iravanian S, Dudley SC Jr. The renin-angiotensin-aldosterone system (RAAS) and cardiac arrhythmias. *Heart Rhythm* 2008;5:S12–S17.
- Fatini C, Sticchi E, Gensini F, et al. Lone and secondary nonvalvular atrial fibrillation: role of a genetic susceptibility. *Int J Cardiol* 2007;120:59–65.
- Takezako T, Zhang B, Serikawa T, Fan P, Nomoto J, Saku K. The D allele of the angiotensin-converting enzyme gene and reperfusion-induced ventricular arrhythmias in patients with acute myocardial infarction. *Jpn Circ J* 2001;65:603–609.
- Walsh EP. Automatic atrial and junctional tachycardias. In: Walsh EP, Triedman JK, eds. *Cardiac Arrhythmias in Children and Young Adults with Congenital Heart Disease*. Philadelphia: Lippincott Williams & Wilkins; 2001:115–136.
- Koh WP, Yuan JM, Sun CL, et al. Angiotensin I-converting enzyme (ACE) gene polymorphism and breast cancer risk among Chinese women in Singapore. *Cancer Res* 2003;63:573–578.
- Rodriguez S, Gaunt TR, Day IN. Hardy-Weinberg equilibrium testing of biological ascertainment for Mendelian randomization studies. *Am J Epidemiol* 2009;169:505–514.
- Villain E, Vetter VL, Garcia JM, Herre J, Cifarelli A, Garson A Jr. Evolving concepts in the management of congenital junctional ectopic tachycardia: a multicenter study. *Circulation* 1990;81:1544–1549.
- Rigat B, Hubert C, Alhenc-Gelas F, Cambien F, Corvol P, Soubrier F. An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. *J Clin Invest* 1990;86:1343–1346.
- Hamdi HK, Castellon R. A genetic variant of ACE increases cell survival: a new paradigm for biology and disease. *Biochem Biophys Res Commun* 2004;318:187–191.
- Danser AH, Schalekamp MA, Bax WA, et al. Angiotensin-converting enzyme in the human heart. Effect of the deletion/insertion polymorphism. *Circulation* 1995;92:1387–1388.
- Watanabe H, Kaiser DW, Makino S, et al. ACE I/D polymorphism associated with abnormal atrial and atrioventricular conduction in lone atrial fibrillation and structural heart disease: implications for electrical remodeling. *Heart Rhythm* 2009;6:1327–1332.
- Shyu KG. Cellular and molecular effects of mechanical stretch on vascular cells and cardiac myocytes. *Clin Sci (Lond)* 2009;116:377–389.
- Hussain W, Patel PM, Chowdhury RA, et al. The renin-angiotensin system mediates the effects of stretch on conduction velocity, connexin43 expression, and redistribution in intact ventricle. *J Cardiovasc Electrophysiol* 2010;21:1276–1283.
- Shyu KG, Chen CC, Wang BW, Kuan P. Angiotensin II receptor antagonist blocks the expression of connexin43 induced by cyclical mechanical stretch in cultured neonatal rat cardiac myocytes. *J Mol Cell Cardiol* 2001;33:691–698.
- Darbar D, Motsinger AA, Ritchie MD, Gainer JV, Roden DM. Polymorphism modulates symptomatic response to antiarrhythmic drug therapy in patients with lone atrial fibrillation. *Heart Rhythm* 2007;4:743–749.
- McNamara DM, Holubkov R, Janosko K, et al. Pharmacogenetic interactions between beta-blocker therapy and the angiotensin-converting enzyme deletion polymorphism in patients with congestive heart failure. *Circulation* 2001;103:1644–1648.